These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11249586)

  • 41. [Synthesis and psychotropic acitivity of some 5-(omega-(4-arylpiperazin-1-yl)-alkanoyl)-2,3-dihydrobenzofurans and related compounds (author's transl)].
    Hirose N; Kuriyama S; Yamatsu K; Kohima T; Toyoshima S
    Yakugaku Zasshi; 1977 May; 97(5):540-52. PubMed ID: 560460
    [No Abstract]   [Full Text] [Related]  

  • 42. The dopamine D3 receptor: From preclinical studies to the treatment of psychiatric disorders.
    Drago F
    Eur Neuropsychopharmacol; 2015 Sep; 25(9):1399-400. PubMed ID: 26278782
    [No Abstract]   [Full Text] [Related]  

  • 43. Pharmacotherapies for cocaine dependence.
    O'Leary G; Weiss RD
    Curr Psychiatry Rep; 2000 Dec; 2(6):508-13. PubMed ID: 11123003
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interpreting published results of extra-label drug use with special reference to reports of drugs used to correct problem behavior in animals.
    Hart BL; Cliff KD
    J Am Vet Med Assoc; 1996 Oct; 209(8):1382-5. PubMed ID: 8870728
    [No Abstract]   [Full Text] [Related]  

  • 45. [Serenics. A new drug group with specific anti-aggressive effect].
    Wasielewski S
    Med Monatsschr Pharm; 1991 Oct; 14(10):290-1. PubMed ID: 1956352
    [No Abstract]   [Full Text] [Related]  

  • 46. Overview of trends in modern psychopharmacology.
    Stahl SM
    CNS Spectr; 2007 Feb; 12(2):103-5. PubMed ID: 17277709
    [No Abstract]   [Full Text] [Related]  

  • 47. [Extrapolation of experimental data on the methods for the clinical evaluation of drugs].
    Karkishchenko NN
    Farmakol Toksikol; 1982; 45(3):22-7. PubMed ID: 7095124
    [No Abstract]   [Full Text] [Related]  

  • 48. Amperozide: a new pharmacological approach in the treatment of schizophrenia.
    Christensson E; Björk A
    Pharmacol Toxicol; 1990; 66 Suppl 1():5-7. PubMed ID: 2406715
    [No Abstract]   [Full Text] [Related]  

  • 49. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.
    Peck CC; Barr WH; Benet LZ; Collins J; Desjardins RE; Furst DE; Harter JG; Levy G; Ludden T; Rodman JH
    Pharm Res; 1992 Jun; 9(6):826-33. PubMed ID: 1409369
    [No Abstract]   [Full Text] [Related]  

  • 50. Blonanserin. AD 5423.
    Drugs R D; 1999 Jul; 2(1):49-50. PubMed ID: 10610294
    [No Abstract]   [Full Text] [Related]  

  • 51. [Bioavailability of 3.519 CERM: influence of dosage form additives (author's transl)].
    Aïache JM; Pognat JF; Boudal P
    J Pharm Belg; 1980; 35(2):85-97. PubMed ID: 7391930
    [No Abstract]   [Full Text] [Related]  

  • 52. Agonist Medications for the Treatment of Cocaine Use Disorder.
    Negus SS; Henningfield J
    Neuropsychopharmacology; 2015 Jul; 40(8):1815-25. PubMed ID: 25563633
    [No Abstract]   [Full Text] [Related]  

  • 53. Pharmacological activity and distribution in vivo fo paramagnetic models of some psychotropic compounds.
    Zhdanov RI; Kadenatsi IB; Moshikovskii JS; Lavretskaya EP; Piruzyan LA
    Life Sci; 1979 Dec; 25(26):2163-71. PubMed ID: 542095
    [No Abstract]   [Full Text] [Related]  

  • 54. "Human guinea pig" asks for animal studies.
    Gøtzsche PC
    BMJ; 2014 Dec; 349():g6714. PubMed ID: 25550276
    [No Abstract]   [Full Text] [Related]  

  • 55. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.
    Sokoloff P; Leriche L; Diaz J; Louvel J; Pumain R
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):107-24. PubMed ID: 23001156
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activators of G-protein signaling 3: a drug addiction molecular gateway.
    Bowers MS
    Behav Pharmacol; 2010 Sep; 21(5-6):500-13. PubMed ID: 20700046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.
    Xi ZX; Gardner EL
    Curr Drug Abuse Rev; 2008 Nov; 1(3):303-27. PubMed ID: 19430578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats.
    Antkiewicz-Michaluk L; Filip M; Michaluk J; Romańska I; Przegaliński E; Vetulani J
    J Neural Transm (Vienna); 2007 Mar; 114(3):307-17. PubMed ID: 16897599
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats.
    Xi ZX; Gilbert J; Campos AC; Kline N; Ashby CR; Hagan JJ; Heidbreder CA; Gardner EL
    Psychopharmacology (Berl); 2004 Oct; 176(1):57-65. PubMed ID: 15083257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.
    Vorel SR; Ashby CR; Paul M; Liu X; Hayes R; Hagan JJ; Middlemiss DN; Stemp G; Gardner EL
    J Neurosci; 2002 Nov; 22(21):9595-603. PubMed ID: 12417684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.